Pfizer collectively addresses 15 therapy areas in domestic formulations with a portfolio of over 150 products that include therapeutics & vaccines. The company has been continuously restructuring its portfolio in the last few years to improve the productivity of its core brands. Fourth largest multinational pharma company in India • Manufacturing facility in Goa with run rate of 1 billion tablets per annum.
OutlookDowngrade from BUY to HOLD as we keep watch on uptick in growth tempo for ex-top 10 brands and implications of the VRS scheme for field force. Valued at Rs 4810 i.e. 30x P/E on FY24E EPS of Rs 160.3.
For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
